Mesoblast (MESO) Share-based Compensation (2016 - 2023)
Mesoblast (MESO) reported Share-based Compensation of -$791000.0 for Q1 2023, up 58.13% on a YoY basis from -$500234.0 in Q1 2022, and up 43.78% sequentially from -$1.4 million in Q4 2022.
Mesoblast (MESO) Share-based Compensation (2016 - 2023) Analysis & Trends
Mesoblast (MESO) has 8 years of Share-based Compensation data on file, last reported at -$791000.0 in Q1 2023.
- For the quarter ending Q1 2023, Share-based Compensation rose 58.13% year-over-year to -$791000.0; the trailing twelve-month figure through Mar 2023 stood at -$1.5 million (down 107.87% YoY), and the FY2022 full-year result was $5.5 million, down 55.75% from the prior year.
- Share-based Compensation climbed to -$791000.0 in Q1 2023, from -$1.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $23.0 million in Q2 2021 to a low of -$4.9 million in Q3 2020.
- A 5-year average of $2.2 million and a median of -$1.1 million in 2021 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 909.62% in 2020, while the deepest fall reached 507.09% in 2020.
- Tracing MESO's Share-based Compensation over 5 years: stood at -$1.6 million in 2019, then soared by 909.62% to $13.3 million in 2020, then tumbled by 111.13% to -$1.5 million in 2021, then climbed by 4.93% to -$1.4 million in 2022, then soared by 43.78% to -$791000.0 in 2023.
- Business Quant data shows MESO's Share-based Compensation at -$791000.0 in Q1 2023, -$1.4 million in Q4 2022, and -$350000.0 in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | Mesoblast | 19.81 Bn | 19.68 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | -791,000.00 |
| Mar 31, 2023 | -791,000.00 |
| Dec 31, 2022 | -1.41 Mn |
| Dec 31, 2022 | -1.41 Mn |
| Sep 30, 2022 | -350,000.00 |
| Sep 30, 2022 | -350,000.00 |
| Jun 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | -1.89 Mn |
| Mar 31, 2022 | -1.89 Mn |
| Dec 31, 2021 | -1.48 Mn |
| Dec 31, 2021 | -1.48 Mn |
| Sep 30, 2021 | -1.08 Mn |
| Sep 30, 2021 | -1.08 Mn |
| Jun 30, 2021 | 22.95 Mn |
| Jun 30, 2021 | 22.95 Mn |
| Mar 31, 2021 | -2.02 Mn |
| Mar 31, 2021 | -2.02 Mn |
| Dec 31, 2020 | 13.30 Mn |
| Dec 31, 2020 | 13.30 Mn |